%0 Journal Article
%A Vlegels, Naomi
%A Knuth, Nicoló L
%A Steiner, Konstantin A
%A Zhang, Linjie
%A Vix, Apolline L
%A Moumin, Dilara
%A Mirzen, Irem
%A Khalifeh, Nada
%A Forster, Charlotte
%A Gesierich, Benno
%A Müller, Franziska
%A Lohse, Philipp
%A Filler, Jule
%A Fang, Rong
%A Klein, Matthias
%A Dimitriadis, Konstantinos
%A Franzmeier, Nicolai
%A Liebig, Thomas
%A Endres, Matthias
%A Görtler, Michael
%A Petzold, Gabor C
%A Wunderlich, Silke
%A Zerr, Inga
%A Field, Thalia S
%A Pham, Mirko
%A Swartz, Richard H
%A Poli, Sven
%A Berrouschot, Jörg
%A Zafar, Atif
%A Schneider, Hauke
%A Shankar, Jai J
%A Aamodt, Anne Hege
%A Minnerup, Jens
%A Mandzia, Jennifer L
%A Reimann, Gernot
%A Psychogios, Marios-Nikos
%A Mundiyanapurath, Sibu
%A Reich, Arno
%A Yeo, Leonard L L
%A Duering, Marco
%A Reidler, Paul
%A Goyal, Mayank
%A Tymianski, Michael
%A Hill, Michael D
%A Dichgans, Martin
%A Tiedt, Steffen
%T Brain-derived tau for monitoring brain injury in acute ischemic stroke.
%J Science translational medicine
%V 18
%N 832
%@ 1946-6234
%C Washington, DC
%I AAAS
%M DZNE-2026-00073
%P eadz1280
%D 2026
%X A specific and accurate blood test for acute brain injury could help monitor infarct growth in ischemic stroke and serve as a surrogate end point in clinical trials. Using a single-molecule detection assay, we assessed plasma brain-derived tau (BD-tau), a marker selectively quantifying tau protein from the central nervous system, in a prospective cohort of 502 patients with acute ischemic stroke with serial blood sampling from admission to day 7. Higher BD-tau concentrations at admission were associated with more extensive early brain injury on computed tomography and predicted larger final infarct volumes. BD-tau increases from admission to day 2 were related to infarct growth. BD-tau concentrations rose until day 7 and were higher in patients with secondary events, including recurrent stroke. After thrombectomy, the rise of BD-tau was smaller in patients with complete versus incomplete recanalization. BD-tau outperformed other blood markers and imaging metrics in predicting 90-day functional outcome across infarct size strata and time points. In an independent multicenter prospective cohort (N = 519), BD-tau showed higher performance than magnetic resonance imaging-derived final infarct volume in predicting functional outcomes at 3, 12, and 36 months. In the biomarker substudy of a phase 3 trial assessing nerinetide in patients with ischemic stroke (N = 193), BD-tau showed predictive performance comparable to the other cohorts, mediated the relationship between recanalization and functional outcome, and showed a 49
%K Humans
%K Male
%K tau Proteins: blood
%K tau Proteins: metabolism
%K Ischemic Stroke: blood
%K Ischemic Stroke: complications
%K Ischemic Stroke: diagnostic imaging
%K Female
%K Aged
%K Biomarkers: blood
%K Brain: metabolism
%K Brain: pathology
%K Middle Aged
%K Brain Injuries: blood
%K Brain Injuries: complications
%K Prospective Studies
%K Magnetic Resonance Imaging
%K Tomography, X-Ray Computed
%K tau Proteins (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41533774
%R 10.1126/scitranslmed.adz1280
%U https://pub.dzne.de/record/284030